TOFACITINIB (TOE fa SYE ti nib) treats rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. It is also used to treat ankylosing spondylitis and ulcerative colitis. It works on the immune system. It belongs to a group of medicines called JAK inhibitors.

XELJANZ Lifestyle Interactions

  • Tofacitinib 5mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: It is best to avoid taking Tofacitinib with grapefruit juice and to avoid grapefruit juice completely during your Tofacitinib treatment. Grapefruit juice may increase the levels of Tofacitinib and the risk for side effects from your treatment. Talk to your health care professional or pharmacist for recommendations.
    • Notes for Professionals: It is best to avoid taking Tofacitinib with grapefruit juice. The exposure to tofacitinib may be significantly increased in patients who regularly consume grapefruit or grapefruit juice, a strong CYP3A4 inhibitor. FDA-approved labeling recommends in patients receiving 5 mg or less twice daily, reduce to once daily dosing; in patients receiving 10 mg twice daily, reduce to 5 mg twice daily; in patients receiving 22 mg once daily of the extended-release (XR) formulation, switch to 11 mg XR once daily; in patients receiving 11 mg XR once daily, switch to the immediate-release formulation at a dose of 5 mg once daily. No specific guidance is provided for grapefruit or grapefruit juice. Coadministration with another strong CYP3A4 inhibitor increased tofacitinib exposure by 2-fold.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.